Sight Sciences Reports 19.5% Revenue Growth to $23.4 Million in Q2 2026

Sight Sciences, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $23.4 million, a 19.5% increase from $19.6 million in the same period last year. For the first half of 2026, the company generated $43.1 million in revenue, up 16.2% from $37.1 million in the prior year. The growth was primarily driven by a 7.7% increase in the Interventional Glaucoma segment, which accounted for $20.7 million in revenue, and a significant 703.3% increase in the Interventional Dry Eye segment, which brought in $2.7 million. The latter's growth was attributed to increased sales volume and improved reimbursement rates for the TearCare procedure.

The company's gross profit for the second quarter was $21.4 million, reflecting a gross margin of 91.4%, compared to 84.8% in the prior year. This increase was largely due to tariff refunds and higher average selling prices. Operating expenses decreased to $25.3 million from $28.3 million year-over-year, leading to a loss from operations of $3.9 million, a significant improvement from the $11.7 million loss reported in the same quarter of 2025. The net loss for the quarter was $4.4 million, down from $11.9 million in the previous year.

Sight Sciences has made strategic moves to enhance its operational capabilities, including a focus on expanding its sales and marketing efforts for the TearCare product line. The company has also been actively working on establishing reimbursement for its Interventional Dry Eye products, which has contributed to the recent revenue growth. As of June 30, 2026, the company had cash and cash equivalents of $79.8 million, down from $91.9 million at the end of 2025, and an accumulated deficit of $402.1 million.

In terms of operational metrics, the company reported a decrease in research and development expenses, which fell to $2.5 million for the second quarter, down 42.7% from the previous year. This reduction was attributed to a decrease in payroll expenses due to a reduced headcount. Selling, general, and administrative expenses also saw a slight decrease, primarily due to lower payroll-related costs and reduced marketing expenses. The company continues to focus on maintaining compliance with its debt obligations under the Hercules Loan Agreement, which has a current outstanding balance of $40 million.

Looking ahead, Sight Sciences anticipates continued investment in product development and market access initiatives, with expectations of ongoing net losses as it seeks to expand its market presence and product adoption. The company remains committed to its strategy of enhancing its product offerings and improving operational efficiencies, while also navigating the challenges posed by market conditions and competition.